James A. Zwiebel

Crizotinib in Patients with Tumors with MET Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2.

Supplementary Figure S1 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Table S1 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Table S4 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Figure S2 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Figure S3 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Table S3 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Figure S5 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Figure S4 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Figure S6 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Table S2 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Data from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

Supplementary Table S5 from Crizotinib in Patients with Tumors with <i>MET</i> Amplification or Exon 14 Deletion: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols C1 and C2

PIK3CB Inhibitor GSK2636771 in Cancers With <i>PTEN</i> Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Phase II Study of Sunitinib in Tumors With &lt;i&gt;c-KIT&lt;/i&gt; Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.

Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.

Trametinib in Patients With <i>NF1-</i>, <i>GNAQ-</i>, or <i>GNA11</i>-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.

Data from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Data from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Supplementary Table S1 from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Data from Phase II Study of Palbociclib (PD-0332991) in &lt;i&gt;CCND1&lt;/i&gt;, &lt;i&gt;2&lt;/i&gt;, or &lt;i&gt;3&lt;/i&gt; Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B

Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF^V600E</i> Mutations: Results of the NCI-MATCH Trial Subprotocol H